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ess: sppeters@wfubmc.Summary An estimated 300 million people are affected by asthma worldwide and
the burden is likely to rise substantially in the next few decades. Estimates of the
prevalence of asthma range from 7% in France and Germany to 11% in the USA and
15–18% in the United Kingdom. Approximately 20% of these patients have severe
asthma, of which 20% is inadequately controlled. Patients with inadequately
controlled severe persistent asthma are at a particularly high risk of exacerbations,
hospitalization and death, and often have severely impaired quality of life. Current
management of asthma focuses on a stepwise approach tailored to disease severity.
In addition to needing high-dose inhaled corticosteroids (ICS) and long-acting b2-
agonists (LABAs), patients with severe persistent asthma often require additional
controller medications, such as anti-leukotrienes, oral LABAs, oral corticosteroids
and/or anti-IgE therapy. There is currently little evidence on which to base
treatment decisions in patients with inadequately controlled severe persistent
asthma already treated with ICS and LABAs. The anti-IgE monoclonal antibody
omalizumab is the most recent addition to the list of treatment options for these
patients and has been shown to reduce exacerbations and emergency visits and
improve lung function, symptom scores and quality of life in patients with difficult-
to-treat asthma whose symptoms remain inadequately controlled despite receiving
ICS and LABAs. Comparative trials are needed to determine the merits of different
treatments and strategies for patients with inadequately controlled severe
persistent asthma and to identify patients likely to benefit from new treatment
options.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Asthma affects 300 million people worldwide and is
predicted to affect an additional 100 million people
by 2025.1 It causes approximately 239,000 deaths
per year (0.4% of all deaths due to disease)2 and
results in a large burden of disability, accounting
for a similar number of disability adjusted life years
(DALYs) as osteoarthritis, cirrhosis, diabetes and
schizophrenia.1,2
Inadequate control of asthma continues to pre-
sent a serious problem, despite advances in our
understanding of the inflammatory basis of asthma
and a growing acceptance of disease management
guidelines. Patients with inadequately controlled
asthma often have limited therapeutic options and
remain at a high risk of serious morbidity and
mortality.3–5 In this review, we will discuss current
strategies for controlling asthma, describe the
causes and consequences of inadequate control,
and evaluate new options for improving asthma
control.Figure 1 GINA guidelines for the clAsthma control: guidelines and
definitions
Global Initiative for Asthma (GINA) guidelines
classify asthma severity into four steps according
to clinical features before treatment, as well as by
the daily medication regimen and the response to
treatment (Fig. 1).3,4 Thus, asthma is classified as
intermittent, mild persistent, moderate persistent
or severe persistent according to clinical features
(Fig. 1). Treatment should be tailored to asthma
severity. For example, patients with intermit-
tent asthma should receive a rapid-acting inhaled
b2-agonist while those with mild persistent asthma
should also receive a low-dose inhaled corticoster-
oid (ICS). Patients with moderate or severe asthma
should receive inhaled long-acting b2-agonists
(LABAs) coadministered with an ICS (LABAs should
never be used as monotherapy for the treatment of
asthma).
The GINA guidelines define control of asthma as
minimal chronic symptoms, minimal (infrequent)assification of asthma severity.3
Management of uncontrolled asthma 1141exacerbations, no emergency visits, minimal use of
as-needed (rapid-acting) b2-agonists, no limitations
on activities, daily peak expiratory flow (PEF)
variation of less than 20%, near normal PEF and
minimal adverse effects from medications.3,4 In the
stepwise approach to therapy recommended in
the GINA guidelines, treatment should progress to
the next step if control is not achieved or is lost
with the current treatment and the patient is using
medication correctly. Thus, a patient with mild
persistent asthma despite step 2 treatment should
be treated using step 3, proceeding to step 4 if
control is still not achieved.
The response to treatment is also incorporated in
various other terms used to categorize asthma at
the severe end of the spectrum. For example, the
European Respiratory Society (ERS) adopted a
concept of ‘difficult/therapy-resistant asthma’ for
patients whose asthma is not controlled despite
high-dose ICS.5 Adult patients are defined as having
difficult/therapy-resistant asthma if their symp-
toms remain uncontrolled despite daily ICS doses in
excess of 2000 mg beclometasone dipropionate
(BDP), 1600 mg budesonide, 1000 mg fluticasone or
equivalent. In children, the dose thresholds above
which asthma is considered difficult to treat are
800 mg of BDP, 800 mg of budesonide or 400 mg of
fluticasone.
The American Thoracic Society (ATS) describes
‘refractory’ asthma as encompassing several sub-
groups of patients with asthma that is severe,
corticosteroid dependent/resistant, difficult to
control, brittle or irreversible.6 Patients with
refractory asthma are those who require high doses
of controller and reliever medications to maintain
symptom control, or who have persistent symp-
toms, exacerbations or airflow obstruction despite
near continuous high-dose medication use. They
also have at least two of the following features:
need for additional daily controller medication;
need to use a short-acting inhaled b2-agonist daily
or near-daily; persistent airway obstruction (forced
expiratory volume in 1 s (FEV1)o80% predicted and
PEF variability420%); one or more urgent care
visits per year; three or more oral steroid ‘bursts’
per year; prompt deterioration with reduction in
steroid dose; or a near-fatal asthma event in the
past.
Pathologic (airway and bronchoalveolar lavage)
studies of severe asthma suggest that one-half to
two-thirds of patients with severe asthma have
persistent airway tissue eosinophilia, despite re-
ceiving high-dose oral and ICSs.7 The presence of
eosinophils (as measured by sputum, lavage, biopsy
or exhaled nitric oxide) may represent another
subtype of severe asthma, characterized by ahigher level of active symptoms, reduced FEV1
and a greater likelihood of exacerbations and near-
fatal events occurring than in a subtype without
eosinophils.8 Differentiation by presence or ab-
sence of eosinophils has been applied to early and
late-onset severe asthma, with indication for both
similarities and differences in the eosinophilic
process dependent on age onset.9 In some, but
not all, cases where eosinophils are absent there
may be an increase in neutrophils. The increase in
neutrophils does not always accompany the ab-
sence of eosinophils, and the two cell types may be
concomitantly present in tissue.8,10 The mechan-
isms or clinical implications for this neutrophilic
inflammation are unclear.Co-morbid risk factors for severe asthma
Certain co-morbidities are associated with severe
or difficult-to-manage asthma.
Asthma co-exists with rhinitis in a large propor-
tion of patients and epidemiological studies have
estimated that the majority of patients with
asthma (60–80%) also have rhinitis, with 20–40%
of patients with rhinitis also having asthma.11–13
A recent study conducted in the United Kingdom
found that adults with asthma and documented
concomitant allergic rhinitis experienced signifi-
cantly more asthma-related hospitalizations and
GP visits as well as incurring higher asthma-related
drug costs compared with adults with asthma
alone.14 The high frequency of co-morbidity of
rhinitis and asthma and the similarity of their
epidemiological, pathological and physiological
features have resulted in recommendations for
a common approach to management.15 Indeed,
effective rhinitis management has been shown
to improve asthma control16 and two recent studies
have shown that treating allergic rhinitis, parti-
cularly with intranasal steroids, confers signifi-
cant protection against asthma exacerbations
that result in emergency department visits for
asthma.17,18
Gastroesophageal reflux disease (GERD) affects
approximately 20% of adults in the United States on
a weekly basis and 40% on a monthly basis.19 GERD
is also a trigger for asthma and the prevalence of
GERD is higher in patients with asthma when
compared with control groups, with 77% of asthma
patients having reflux symptoms and 82% of asth-
matics having abnormal esophageal acid contact
times on 24-h esophageal pH testing.19 Esophageal
acid elicits respiratory responses including de-
creases in airflow, oxygen saturation, and increases
in respiratory resistance, minute ventilation and
S.P. Peters et al.1142respiratory rate. Additionally, therapy of GERD
improves asthma outcomes: in combined studies
examining 326 asthma patients receiving drug
therapy for GERD, asthma symptoms improved in
69% of these patients while surgical therapy trials
to alleviate symptoms of GERD in 417 asthma
patients showed that asthma symptoms improved
in 79% of patients.19
A number of environmental factors have been
shown to be associated with the onset of asthma.
These include exposure to tobacco smoke, allergen
sensitization, viral infection, occupational agents
and air pollutants.4 While these factors can
precipitate exacerbations and prolong symptoms,
their role in the development of severe asthma is
not known. Aspirin and related drugs are more
likely to act as specific triggers for asthma
symptoms in susceptible individuals rather than
being responsible for the development of asthma.
However, the symptoms provoked by aspirin are
often severe and patients with aspirin-sensitive
asthma account for a substantial proportion of life-
threatening exacerbations.20
Obesity has also been shown to be associated
with asthma,21 but it seems that asthma may
predispose to later weight gain rather than vice
versa, and a common other factor such as depres-
sion during critical periods of early life may be
involved.22 A link with severe disease has not been
clearly established.
Increased stress is not only known to trigger
worsening symptoms and exacerbations23 but may
also be associated with the development of asthma
and atopy, possibly as early as in utero.24 Possible
pathways by which stress may exert an effect
include neuroimmunoregulation and oxidative
stress pathways.24 Although asthma is not itself a
psychosomatic condition, people with severe asth-
ma are prone to anxiety and depression that can
result in non-adherence to medication regimens
and thus loss of asthma control.25Prevalence and control of asthma
It is important to distinguish between the severity
of asthma and the degree of control.26 Severity can
be used to describe the underlying nature or
intensity of asthma in the absence of treatment.
In patients receiving treatment, asthma severity
can be estimated from the minimum level of
treatment required to achieve good control and
the intensity of exacerbations while on appropriate
controller therapy. Asthma severity and control are
distinct terms and it is important to note thatpatients with severe asthma can have good control,
while patients with mild asthma can have poor
control. The level of asthma control is particularly
important to patients as it impacts directly on
quality of life, while physicians need to determine
the degree of control in order to decide whether
treatment adjustments are required.
The recent European Community Respiratory
Health Survey (ECRHS) estimated that 4.5% of
people aged 20–44 years had asthma.27 The overall
prevalence of asthma in adults and children varies
between countries, with estimates of 7% in France
and Germany, 11% in the USA and 15–18% in the
United Kingdom.1
A survey of 2803 European patients showed that
asthma is frequently poorly controlled and that
levels of control do not meet the goals of the GINA
guidelines.28 Forty-six percent of patients reported
daytime symptoms and 30% had asthma-related
sleep disturbances at least once a week. In the past
year, 25% of patients with asthma had an unsched-
uled urgent care visit, 10% had an emergency room
visit and 7% had an overnight hospitalization.
Similarly, a survey of 7786 adults and 3153 children
with asthma in Europe, North America and Asia
showed that many patients failed to meet one or
more of the GINA goals.29 The GINA goal of minimal
chronic symptoms was not met in a large percen-
tage of patients, with 45–84% of patients having
daytime symptoms and 33–70% having night-time
awakenings during the previous 4 weeks. In addi-
tion, many patients did not meet the goal of
minimal exacerbations and no emergency visits,
with 9–31% having hospital admission due to
asthma. The other GINA goals of minimal need for
short-acting inhaled b2-agonists and normal or
near-normal lung function were also not met by a
large proportion of patients. Similar findings were
reported from a telephone survey of European
asthma patients, which showed that only 35% had
good asthma control (failed to meetp1 GINA goal),
40% had moderate control (failed to meet 2–3 GINA
goals) and 25% had poor control (failed to meet 4–5
GINA goals).30
In many cases, the inadequate control of asthma
reported in these surveys was associated with
inadequate use of anti-inflammatory controller
medication and differences between patient per-
ceptions of control and actual symptoms.28,29
However, studies have also shown that many
patients have inadequate asthma control despite
GINA step 4 therapy. For example, the Gaining
Optimal Asthma Control (GOAL) study investigated
whether treatment with fluticasone propionate or
salmeterol/fluticasone combination therapy could
achieve guideline-based asthma control in patients
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at three categories of patients according to their
corticosteroid usage: stratum 1, corticosteroid
naive; stratum 2, p500 mg/day BDP or equivalent;
and stratum 3,4500–1000 mg/day BDP. Patients
were treated in two phases. During phase I,
treatment was stepped up every 12 weeks until
total control of asthma was achieved. Patients
entered phase II if they achieved total control or if
they had not achieved total control after 12 weeks
at the maximum dose. In phase II, treatment was
continued at the dose at which control was
achieved (or at the maximum dose). At the end of
phase II, 22% of salmeterol/fluticasone-treated
patients in stratum 1, 25% in stratum 2 and 38% in
stratum 3 did not achieve well controlled asthma,
with higher percentages in the fluticasone arm.
These results show that, although treatment goals
can be met in many patients by guideline-based use
of ICS and inhaled LABAs, many patients still fail to
achieve adequate control of their asthma. Impor-
tantly, in patients with the most severe asthma,
adding an oral corticosteroid at the end of the
study, combined with the highest recommended
dose of fluticasone and salmeterol, resulted in only
another 7% of patients achieving well-controlled
asthma.
The prevalence of severe asthma as a percentage
of all asthma varies from country to country, with
estimates of 18% in Western Europe, 19% in the USA
and 32% in Central Europe.28,29 An estimated 20% of
these patients with severe asthma have uncon-
trolled disease.29 It has also been estimated that
approximately 50% of patients with severe asthma
have a positive skin-prick test for common aero-
allergens,32 which would suggest that approxi-
mately 2% of all asthma patients have
uncontrolled severe persistent allergic asthma.
New treatments targeting this relatively small
group of asthma patients might be expected to
have a disproportionately large effect on the
overall disease burden.Personal, social and economic burdens of
asthma
Patients with inadequately controlled severe per-
sistent asthma despite GINA step 4 therapy are a
particularly challenging patient population with
significant unmet medical needs. These patients
are at high risk of severe exacerbations and
death33,34 and have few therapeutic options avail-
able. In addition, patients with asthma often have
co-morbid conditions, including psychiatric illness(depression, anxiety, panic, phobia or other psy-
chiatric diagnoses).35 The high prevalence of
psychiatric illness was also apparent in a systematic
assessment of patients with difficult-to-treat asth-
ma.36 Retrospective analyses of patients who have
died of asthma suggest that psychosocial factors
(including social isolation, marital problems, alco-
holism, anxiety and depression) contributed to poor
asthma control, although the relationship between
the pathophysiology of asthma and psychosocial
factors is difficult to determine.5 The high pre-
valence of psychiatric illness is likely to add to the
difficulty in maintaining patient compliance, which
is a frequent underlying factor in poor asthma
control.
Asthma adversely affects numerous aspects of
daily life, including sleep, work, study, exercise and
daily activities,37 and causes a similar level
of disability to diabetes.1 An English survey in
2001 found that 16% of men and 20% of women
with asthma symptoms said that their sleep
was disturbed at least once a week and 50%
(46% of men, 54% of women) said that they
were unable to carry out their everyday activ-
ities.38 The degree of asthma-related impairment
of quality of life increases with disease severity,
with the most profound effects seen in patients
with chronically uncontrolled severe disease.39
These patients are frequently admitted to hospital
and have regular absences from work or school.
In surveys conducted during 1999–2001, 7% of
Western Europeans with asthma were admitted to
hospital due to asthma during the previous 12
months and 10% required an emergency room
visit.29 Between 80% and 85% of asthma deaths
occur in patients with poorly controlled severe
disease,40 and there is a strong association between
increased recurrences of hospitalization and asth-
ma severity.41
The European Network for Understanding
Mechanisms of Severe Asthma (ENFUMOSA)
investigated the characteristics of patients with
poorly controlled severe asthma.32 The 163 pa-
tients with severe asthma enrolled in the
ENFUMOSA study had all had at least one exacer-
bation despite treatment with X1200 mg/day of
BDP or equivalent and almost 40% had been
hospitalized in the previous year. As well as ICS,
96% of patients were treated with inhaled LABAs,
46% required oral theophylline and a small pro-
portion (o20%) were treated with anticholinergics,
chromones or frequent nebulized short-acting
b2-agonists. In addition, 33% of the group also
required oral corticosteroids (median prednisone
dose 19mg). Patients with uncontrolled severe
asthma were more likely to be female and had
Table 1 Differences in clinical phenotype of patients with severe asthma and controlled asthma.32
Controlled asthma (n ¼ 158) Severe asthma (n ¼ 163) P value
Sex ratio, female:male 1.6:1 4.4:1 o0.001
Weight (kg) (females) 66.5 70.9 o0.05
BMI, females 25.6 27.2 o0.05
Systolic BP (mmHg)
Males 127.0 131.4 o0.01
Females 123.1 130.2 o0.01
Diastolic BP (mmHg)
Males 79.6 83.1 o0.001
Females 76.8 82.0 o0.001
Heart rate (beats/min)
Males 67.7 82.3 o0.001
Females 73.9 82.7 o0.001
Dose of ICS (mg/day) 666 1676 o0.001
Mean total serum IgE (IU/ml) 109 148 o0.05
X1 positive allergen skin-prick test (%) 59 78 o0.05
FEV1 (% predicted) 88.5 71.8 o0.001
FEV1 post-salbutamol (% predicted) 97.6 80.9 o0.001
FVC (% predicted) 103.1 94.1 o0.001
FEV1/FVC 89.7 79.9 o0.001
RV/TLC 104.2 113.4 o0.01
KCO 95.0 90.6 o0.05
PaO2 (kPa) 12.0 11.2 o0.001
PaCO2 (kPa) 5.1 4.9 o0.01
Pulmonary function and blood gases were measured in 130 subjects with controlled asthma and 133–153 subjects with severe
asthma. BMI, body mass index; BP, blood pressure; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in 1 s; FVC, forced
vital capacity; RV, residual volume; TLC, total lung capacity; KCO, carbon monoxide transfer coefficient; PaO2, arterial oxygen
tension; PaCO2, arterial carbon dioxide tension.
S.P. Peters et al.1144a higher body mass index than patients with
mild-to-moderate asthma (Table 1). In addition,
aspirin sensitivity was more common in the severe
group, reflected in higher urinary levels of the
leukotriene LTE4.
The ongoing US multicentre TENOR study is
currently investigating a cohort of patients with
severe or difficult-to-treat asthma.42 The ongoing
study recruited 4756 patients aged X6 years with
difficult-to-treat asthma, defined as having high
healthcare utilization in the past year (X2 un-
scheduled visits or X2 oral steroid bursts), or high
medication use (X3 medications or long-term daily
high-dose ICS or X5mg/day prednisone). Consis-
tent with ENFUMOSA, the majority of adult patients
with severe or difficult-to-control asthma were
female (71%), although the children and adoles-
cents were more likely to be male (67% and 57%,
respectively). Immunoglobulin E (IgE) levels were
elevated in all age groups and increased with
severity of asthma in children and adolescents but
not adults. Patients with IgE levelsX100 IU/ml had
a lower FEV1 than those with IgEo100 IU/ml, the
difference in lung function being greatest in
children.43 In general, lower FEV1 values wereassociated with greater healthcare utilization
(Fig. 2).44
In addition to the impact on affected patients,
asthma places a large economic burden on
healthcare systems and society. In Europe, the
total cost of asthma has been approximated at
h17.7 billion per annum, of which an estimated
h9.8 billion is accounted for by the indirect costs of
lost productivity due to absence from work.45
Severe asthma accounts for a large proportion of
the overall costs,46 with uncontrolled disease
responsible for much of the economic burden.47,48
In a Spanish study, patients with severe asthma
accounted for 51% of total costs for the whole
group.49 Similar findings have been reported in
France50 and Italy47 (Fig. 3). Patients with poorly
controlled asthma utilize significantly greater
amounts of healthcare resources than ‘controlled’
patients.51,52 For example, a study of 13,241 UK
asthma patients with varying degrees of severity
showed that patients with ‘poorly controlled’
asthma had recurrent asthma exacerbations requir-
ing emergency treatment and were around 3–4
times more costly to manage than well-controlled
patients.51
Figure 3 Direct and indirect costs increase with asthma severity.47
Figure 2 Healthcare utilization and missed days from work/school according to asthma severity in a cohort of 4756
patients with severe or difficult-to-treat asthma. *Po0.05 for difference in lung function (FEV1).44
Management of uncontrolled asthma 1145Management approaches for patients
with poorly controlled severe asthma
Physicians face substantial challenges when treat-
ing patients with uncontrolled or severe asthma.
The complexity of a multiple daily medication
regimen is often a factor in patient non-adherence,
which in turn affects asthma control. Patients with
severe asthma may require particularly intensive
patient education and referral to appropriatesources of support to assist in treatment compli-
ance.
Patients with severe persistent asthma fre-
quently require regular use of multiple controller
medications, including high-dose ICS (41000 mg/
day of BDP or equivalent) plus a LABA twice daily. If
needed, one or more of the following are often
added: sustained-release theophylline, anti-leuko-
triene, oral LABA, oral corticosteroids or anti-IgE
therapy (GINA step 4 therapy).3,4
S.P. Peters et al.1146There is currently little evidence on which to
base management decisions in patients with un-
controlled asthma despite GINA step 3 or step 4
treatment. It is now recognized that addition of a
LABA is associated with better outcomes than
increasing corticosteroid doses.31,53–55 However,
there is a lack of comparative data to determine
the relative merits of other agents when added to
high-dose corticosteroid therapy. Anti-leukotrienes
have been shown to provide clinical benefit in
patients with chronic persistent asthma who were
symptomatic despite ICS56 and improve asthma
control in patients receiving high-dose ICS,57
perhaps reflecting the relatively high level of
aspirin sensitivity among patients with severe
asthma. In practice, as seen in the ENFUMOSA
study, oral corticosteroids are used by approxi-
mately one-third of patients with severe asthma.32
However, regular use of oral corticosteroids is
associated with significant side effects.6,26
The anti-leukotrienes are a relatively new class
of anti-asthma drugs that either block leukotriene
synthesis by inhibiting 5-lipoxygenase (an example
being zileuton), or are antagonists of the cysteinyl
leukotriene 1 receptor (CysLT1), such as montelu-
kast, zafirlukast and pranlukast. Hence, the major
effect of the anti-leukotrienes is a selective anti-
inflammatory one. Zafirlukast has been shown to
improve asthma control in patients receiving high-
dose ICSs,57 and the benefit of anti-leukotrienes
may be particularly apparent in the large percen-
tage (20–25%) of patients with severe asthma who
may be aspirin sensitive.32,58
Theophylline is a bronchodilator that may have
extrapulmonary effects, including an anti-inflam-
matory action.59 When given as a sustained-release
preparation, it has a long duration of action and is
useful in the control of nocturnal symptoms that
persist despite regular treatment with anti-inflam-
matory therapy.60 Theophylline is also a possible
additional bronchodilator for use in patients with
severe asthma, although as add-on therapy, it is
less effective than LABAs.61,62 It is, however, a less
expensive option. In practice, the routine use of
theophylline in patients hospitalized for asthma isTable 2 Hospitalizations and other unscheduled visits in
Type of visit Rate per year
Omalizumab Control Tre
Total emergency visits 0.332 0.623 0.2
Hospital admission 0.030 0.062 0.0
Emergency room visits 0.026 0.066 0.0
Unscheduled doctor visits 0.252 0.443 0.1no longer advocated in some countries due to the
potential for serious adverse effects and the lack of
benefit.63 Further clinical research is needed to
verify the value of theophylline in adults and
children with severe asthma exacerbations and
impending respiratory failure.
Omalizumab, a recently developed anti-IgE
monoclonal antibody for the treatment of asthma
has proven to be effective and well tolerated as
add-on therapy in patients with severe persistent
asthma. In a pooled analysis of 2511 omalizumab-
treated patients and 1797 control patients in seven
clinical trials, 93% of patients met the criteria for
severe persistent asthma set out in the GINA 2002
guidelines.64 Analysis of pooled data showed that
addition of omalizumab to current asthma therapy
significantly reduced the rate of asthma exacer-
bations by 38% (0.910 vs. 1.474, Po0.0001
vs. control) and total emergency visits by 47%
(Po0.0001 vs. control; Table 2). Analysis of demo-
graphic subgroups showed that the efficacy of
omalizumab on asthma exacerbations was unaffec-
ted by patient age, gender, baseline serum IgE
(split by median) or by 2- or 4-weekly dosing
schedule, although the greatest absolute benefit
was observed in patients with poor baseline FEV1
values.64 Add-on omalizumab treatment in patients
with co-morbid asthma and rhinitis has also been
shown to lead to significantly fewer asthma
exacerbations and significant improvements in both
asthma and rhinitis-related quality of life, com-
pared with placebo.65 The anti-inflammatory effect
of omalizumab produces a profound reduction in
airway eosinophilia (observed in patients with mild-
to-moderate asthma). Omalizumab also signifi-
cantly reduces the number of T-lymphocytes
(CD3+, CD4+, CD8+), B-cells, mast cells expressing
the high-affinity IgE receptor, and cells showing
surface IL-4.66
Omalizumab has been shown to be particularly
effective in patients with severe asthma. Regres-
sion analysis of data from more than 1000 patients
shows that baseline characteristics reflecting more
severe asthma (high doses of ICS, history of
frequent emergency asthma treatment, poor lungpatients receiving omalizumab.64
Ratio (95% CI) P value
atment difference
91 0.533 (0.401, 0.709) o0.0001
32 0.489 (0.246, 0.972) 0.041
40 0.397 (0.192, 0.820) 0.013
91 0.568 (0.417, 0.774) 0.0003
Figure 4 Venn diagram of odds ratios for response with omalizumab relative to placebo, according to three baseline
high-severity covariates. Response was defined as at least one of the following: reduced symptoms with no increase in
rescue use of b2-agonist, reduced rescue use of b2-agonist with no increase in symptoms, improved lung function,
improved quality of life; plus no exacerbations during 16 weeks of treatment). The likelihood of response increases with
the presence of more than one high-severity covariate.67
Management of uncontrolled asthma 1147function) were predictive of the greatest response
to omalizumab treatment (Fig. 4).67 In addition,
subgroup analyses have shown that omalizumab
was particularly effective in reducing exacerba-
tions in patients at high risk of death, as indicated
by prior intubation or recent hospitalization/
emergency treatment.68
The recently updated GINA guidelines recom-
mend anti-IgE therapy (of which omalizumab is the
only currently available option) for patients with
severe allergic asthma.4 Anti-IgE therapy is listed as
an option in GINA step 4 therapy if additional
control is needed beyond that achieved on high-
dose ICS and LABAs. A recent 28-week study of
omalizumab as add-on therapy (INNOVATE) exclu-
sively enrolled patients with inadequately con-
trolled severe persistent asthma despite GINA step
4 therapy.69 All patients were receiving ICS plus
LABAs and two thirds were receiving additional
controller medication (including oral corticoster-
oids in 22% of patients). Statistically significant
reductions were observed in the rate of clinically
significant asthma exacerbations after adjustment
for baseline exacerbation history (0.68 vs. 0.91,
P ¼ 0.042; Fig. 5a), severe exacerbation rate (0.24
vs. 0.48, P ¼ 0.002; Fig. 5b), and emergency visit
rates (0.24 vs. 0.43, P ¼ 0.038). Omalizumab also
provided significant improvements over placebo in
morning PEF, FEV1, asthma symptom scores and
quality of life scores (Juniper AQLQ) and patients’and investigators’ global evaluations of treatment
effectiveness (both Po0.001).
In addition to the clinical benefits that omalizu-
mab provides in patients with severe persistent
asthma, it is also relevant that the anti-IgE
monoclonal antibody is administered by subcuta-
neous injection every 4 weeks (or every 2 weeks for
patients requiring higher doses).70 The relative
simplicity of treatment may aid adherence for
patients already on a complicated regimen of
multiple inhaled and oral medications. The poten-
tial to improve adherence could be particularly
important in poorly controlled and difficult-to-treat
asthma given the strong association between
compliance and treatment outcomes.71
Potential future therapies for severe asthma
include anti-IL-5 monoclonal antibodies and agents
that block interleukin synthesis or its effects. The
anti-IL-5 monoclonal antibody SCH55700 was eval-
uated in a small study of different single doses in
patients with severe persistent asthma and was
shown to be biologically active (decrease in
circulating eosinophils), with signs of an improve-
ment in FEV1.
72 Another anti-IL-5 antibody
(SB240563, mepolizumab) was shown to deplete
circulating eosinophils and partially reduce airway
eosinophils without having an observable clinical
effect.73 Although mepolizumab had a marked
effect on blood eosinophils (median 100% decrease,
interquartile range 67–100%), the decrease in lung
Figure 5 (a) Effect of omalizumab treatment on the rate of clinically significant asthma exacerbations (adjusted for
baseline exacerbation history) during the 28-week treatment period (PITT population); mean (95% confidence
interval).69 (b) Effect of omalizumab treatment on severe exacerbations (PEF or FEV1o60% of personal best) during the
28-week treatment period (PITT population).
S.P. Peters et al.1148eosinophils was considerably smaller (median 55%,
interquartile range 29–89%),73 which might explain
the lack of clinical effect. In addition, mepolizu-
mab had no effect on T-cell subsets or cytokine
production.74 It remains to be seen whether
mepolizumab can achieve the degree of reduction
in airway eosinophils required to produce a clinical
response or even whether eosinophil depletion is
capable of achieving clinical benefits.
In a study of 85 patients with moderate-to-severe
asthma receiving high-dose ICS (X1500 mg/day
BDP), suplatast (an orally administered agent that
blocks the synthesis of cytokines, including IL-4 and
IL-5, from Th2 cells) proved superior to placebo
for symptoms and lung function when ICS doses
were halved, although the level of exacerbations
was not recorded.75 Further investigation in a
clearly defined group of patients with severe
asthma is required to evaluate its usefulness in this
population.Other experimental drugs, including methotrex-
ate,76 cyclosporine,77 gold salts,78 troleandomy-
cin,79 azathioprine80 and chloroquine81 have failed
to demonstrate an acceptable risk/benefit ratio.Discussion
Despite improved understanding and adherence to
recommended management strategies, many pa-
tients who have inadequately controlled asthma,
particularly those with severe disease, are at high
risk of exacerbations and asthma-related death.
Patients who are not well controlled on high-dose
ICS in combination with other available controller
medications, or who require additional systemic
corticosteroid treatment, have an identifiable
need for a new therapy that can improve
clinical outcomes, in particular life-threatening
Management of uncontrolled asthma 1149exacerbations, without adding to the complexity or
burden of adverse effects of medication.
The addition of omalizumab therapy is a promis-
ing new therapeutic option for patients with severe
persistent asthma that is inadequately controlled
despite best available therapy. Comparative trials
are needed to determine the relative merits of
different treatments and strategies as add-on
therapy for patients with inadequately controlled
asthma despite GINA step 4 therapy (i.e. high-dose
ICS plus LABAs) and additional studies are needed
to identify patients who may benefit from these
new treatment options.Acknowledgements
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